Immune Monitoring Core

主动免疫疗法治疗人类癌症是肿瘤学发展最快的领域之一。这个 建立免疫监测核心实验室，为需要监测的研究人员提供资源 免疫疗法试验。IMCL拥有700平方英尺的实验室空间和两个100平方英尺的细胞培养室 在新的免疫学研究中心(CCIR)设施中。作为最先进的设施而创建，目标是 实验室将在临床试验过程的所有阶段与每位研究人员密切合作，通过规划 适用于每个特定临床试验的免疫监测分析的类型和数据点的数量， 处理标本，进行分析，并提供数据解释方面的帮助。IMCL还允许 研究人员使用个别实验室通常不提供的专用设备。作为这一承诺的一部分 为了向所有研究人员提供最新的免疫监测技术，IMCL与业界合作 和学术合作者开发新的检测方法，验证免疫检测并设定严格的质量 控制标准。IMCL用于免疫监测的技术包括1)细胞因子ELISPOT 检测；2)使用HLAI类和II类多肽四聚体/多聚体的6色FACS表型分析；3) 细胞内细胞因子染色方法；4)先进的基于ELISA的技术，可测量多个 单个样本或反应中的细胞因子(多重细胞因子分析)；5)新的T细胞增殖试验 CFSE标记与流式细胞仪联用：6)更灵敏的非放射性方法检测抗原性 用流式细胞仪检测CTL活性。IMCL在临床试验开发中起着关键作用。在上一次 在资助期间，来自19个CCSG项目中的8个项目的10名研究人员使用了IMCL服务。90%的 用户有同行评审的资金，占使用率的80.7%。着眼于未来的计划 增加IMCL对CCSG相关临床研究的参与，以及开发新的分析方法来 提高可以从临床试验中获得的信息的数量和质量。

Active immunotherapy to treat human cancer is one of the most rapidly developing fields in oncology. The Immune Monitoring Core Laboratory was established as a resource for investigators needing to monitor immunotherapy trials. The IMCL occupies 700 sq ft lab space with two adjacent 100 sq ft cell culture rooms in the new Center for Immunology Research (CCIR) facility. Created as a state-of-the-art facility, the goal of the lab is to work closely with each investigator at all stages of the clinical trial process by planning both the types of immune monitoring assays and number of data points suitable for each particular clinical trial, processing specimens, performing assays, and providing help with data interpretation. The IMCL also allows researchers to use dedicated equipment not usually available in individual labs. As part of this commitment to offer the most recent technology in immune monitoring to all researchers, the IMCL teams with industry and academic collaborators to develop new assays, to validate immune assays and to set rigorous quality control standards. The techniques used by the IMCL for immune monitoring include 1) cytokine ELISPOT assays; 2) 6-color FACS phenotyping assays using HLA class I and class II peptide tetramers/multimers; 3) intracellular cytokine staining methods; 4) advanced ELISA-based technology that measures multiple cytokines in a single sample or reaction (multiplex cytokine analysis); 5) newer T-cell proliferation assays using CFSE labeling coupled to FACS; 6) more sensitive non-radioactive methods to determine antigenspecific CTL activity using FACS. The IMCL plays a key role in clinical trial development. During the previous funding period, IMCL services were used by 10 investigators from 8 of the 19 CCSG programs. 90 % of users had peer-reviewed funding and accounted for 80.7 % of utilization. Future plans are focused on Increasing the IMCL participation in CCSG-related clinical studies, as well as developing new assays to improve the amount and quality of information that can be obtained from a clinical trial.